Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

2.

Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Lucas PC, Lee AV, Oesterreich S, Atkinson JM.

Cancer Lett. 2019 Oct 1;461:21-30. doi: 10.1016/j.canlet.2019.06.011. Epub 2019 Jun 20.

PMID:
31229512
3.

Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y.

Cancer Res. 2019 Jun 1;79(11):3008. doi: 10.1158/0008-5472.CAN-19-1133. No abstract available.

PMID:
31160311
4.

E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.

Bandilovska I, Keam SP, Gamell C, Machicado C, Haupt S, Haupt Y.

Carcinogenesis. 2019 Jul 6;40(6):707-714. doi: 10.1093/carcin/bgz072.

PMID:
31087000
5.

Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects.

Delbridge ARD, Kueh AJ, Ke F, Zamudio NM, El-Saafin F, Jansz N, Wang GY, Iminitoff M, Beck T, Haupt S, Hu Y, May RE, Whitehead L, Tai L, Chiang W, Herold MJ, Haupt Y, Smyth GK, Thomas T, Blewitt ME, Strasser A, Voss AK.

Cell Rep. 2019 Apr 9;27(2):442-454.e5. doi: 10.1016/j.celrep.2019.03.048.

6.

A quantitative model to predict pathogenicity of missense variants in the TP53 gene.

Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM, James PA.

Hum Mutat. 2019 Jun;40(6):788-800. doi: 10.1002/humu.23739. Epub 2019 Mar 18.

PMID:
30840781
7.

The long and the short of it: the MDM4 tail so far.

Haupt S, Mejía-Hernández JO, Vijayakumaran R, Keam SP, Haupt Y.

J Mol Cell Biol. 2019 Mar 1;11(3):231-244. doi: 10.1093/jmcb/mjz007.

8.

An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Böhm M, Henshall S, Delprado W, Stricker P, Horvath LG, Kench JG.

Int J Cancer. 2019 Mar 1;144(5):1151-1159. doi: 10.1002/ijc.31906. Epub 2018 Dec 4.

PMID:
30288742
9.

Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue.

Keam SP, Gulati T, Gamell C, Caramia F, Arnau GM, Huang C, Schittenhelm RB, Kleifeld O, Neeson PJ, Williams SG, Haupt Y.

Radiat Environ Biophys. 2018 Aug;57(3):241-249. doi: 10.1007/s00411-018-0746-5. Epub 2018 May 30.

PMID:
29850926
10.

Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.

Keam SP, Gulati T, Gamell C, Caramia F, Huang C, Schittenhelm RB, Kleifeld O, Neeson PJ, Haupt Y, Williams SG.

Prostate. 2018 Jun;78(8):563-575. doi: 10.1002/pros.23500. Epub 2018 Mar 9.

PMID:
29520850
11.

Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Gulati T, Huang C, Caramia F, Raghu D, Paul PJ, Goode RJA, Keam SP, Williams SG, Haupt S, Kleifeld O, Schittenhelm RB, Gamell C, Haupt Y.

Mol Cell Proteomics. 2018 Jun;17(6):1170-1183. doi: 10.1074/mcp.RA117.000504. Epub 2018 Feb 20.

12.

Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice.

Jackson JT, Ng AP, Shields BJ, Haupt S, Haupt Y, McCormack MP.

Blood Adv. 2018 Feb 27;2(4):347-360. doi: 10.1182/bloodadvances.2017013243.

13.

New insights on the regulation of INK4/ARF locus expression.

Gamell C, Ginsberg D, Haupt S, Haupt Y.

Oncotarget. 2017 Nov 1;8(63):106147-106148. doi: 10.18632/oncotarget.22258. eCollection 2017 Dec 5. No abstract available.

14.

P53 at the start of the 21st century: lessons from elephants.

Haupt S, Haupt Y.

F1000Res. 2017 Nov 22;6:2041. doi: 10.12688/f1000research.12682.1. eCollection 2017. Review.

15.

The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort.

Keam SP, Caramia F, Gamell C, Paul PJ, Arnau GM, Neeson PJ, Williams SG, Haupt Y.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):188-198. doi: 10.1016/j.ijrobp.2017.09.037. Epub 2017 Sep 25.

PMID:
29102647
16.

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer.

Gamell C, Gulati T, Solomon B, Haupt S, Haupt Y.

Mol Cell Oncol. 2017 Mar 7;4(5):e1299273. doi: 10.1080/23723556.2017.1299273. eCollection 2017.

17.

Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis.

Masaldan S, Clatworthy SAS, Gamell C, Meggyesy PM, Rigopoulos AT, Haupt S, Haupt Y, Denoyer D, Adlard PA, Bush AI, Cater MA.

Redox Biol. 2018 Apr;14:100-115. doi: 10.1016/j.redox.2017.08.015. Epub 2017 Sep 1.

18.

E6AP promotes prostate cancer by reducing p27 expression.

Raghu D, Paul PJ, Gulati T, Deb S, Khoo C, Russo A, Gallo E, Blandino G, Chan AL, Takano E, Sandhu SK, Fox SB, Williams S, Haupt S, Gamell C, Haupt Y.

Oncotarget. 2017 Jun 27;8(26):42939-42948. doi: 10.18632/oncotarget.17224.

19.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

20.

MDM4 is a rational target for treating breast cancers with mutant p53.

Miranda PJ, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, Haupt Y.

J Pathol. 2017 Apr;241(5):661-670. doi: 10.1002/path.4877. Epub 2017 Mar 1.

PMID:
28097652
21.

The role of MDM2 and MDM4 in breast cancer development and prevention.

Haupt S, Vijayakumaran R, Miranda PJ, Burgess A, Lim E, Haupt Y.

J Mol Cell Biol. 2017 Feb 1;9(1):53-61. doi: 10.1093/jmcb/mjx007. Review.

22.

Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.

Gamell C, Gulati T, Levav-Cohen Y, Young RJ, Do H, Pilling P, Takano E, Watkins N, Fox SB, Russell P, Ginsberg D, Monahan BJ, Wright G, Dobrovic A, Haupt S, Solomon B, Haupt Y.

Sci Signal. 2017 Jan 10;10(461). pii: eaaf8223. doi: 10.1126/scisignal.aaf8223.

PMID:
28074012
23.

Ubiquitin ligase E6AP mediates nonproteolytic polyubiquitylation of β-catenin independent of the E6 oncoprotein.

Kuslansky Y, Sominsky S, Jackman A, Gamell C, Monahan BJ, Haupt Y, Rosin-Arbesfeld R, Sherman L.

J Gen Virol. 2016 Dec;97(12):3313-3330. doi: 10.1099/jgv.0.000624. Epub 2016 Oct 7.

PMID:
27902311
24.

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, Gamell C, Haupt Y.

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

PMID:
27641331
25.

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins.

Haupt Y, Blandino G.

Front Oncol. 2016 Jul 12;6:170. doi: 10.3389/fonc.2016.00170. eCollection 2016. No abstract available.

26.

The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y.

Cancer Res. 2016 Jul 15;76(14):4236-48. doi: 10.1158/0008-5472.CAN-15-1553. Epub 2016 May 26. Retraction in: Cancer Res. 2019 Jun 1;79(11):3008.

27.

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways.

Haupt S, Raghu D, Haupt Y.

Front Oncol. 2016 Jan 27;6:12. doi: 10.3389/fonc.2016.00012. eCollection 2016. Review.

28.

Clinical Overview of MDM2/X-Targeted Therapies.

Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E.

Front Oncol. 2016 Jan 27;6:7. doi: 10.3389/fonc.2016.00007. eCollection 2016. Review.

29.

Regulation of Mutant p53 Protein Expression.

Vijayakumaran R, Tan KH, Miranda PJ, Haupt S, Haupt Y.

Front Oncol. 2015 Dec 17;5:284. doi: 10.3389/fonc.2015.00284. eCollection 2015. Review.

30.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

31.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
32.

Targeting Mdmx to treat breast cancers with wild-type p53.

Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Lee YY, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, Haupt Y.

Cell Death Dis. 2015 Jul 16;6:e1821. doi: 10.1038/cddis.2015.173.

33.

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.

Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, Haupt S, Pochampally R, Boss GR, Romero DG, Radu CG, Martinez LA.

Nat Commun. 2015 Jun 12;6:7389. doi: 10.1038/ncomms8389.

34.

p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress.

Haupt S, Raghu D, Haupt Y.

Front Oncol. 2015 Mar 10;5:57. doi: 10.3389/fonc.2015.00057. eCollection 2015. No abstract available.

35.

Role of p53 in the progression of gastric cancer.

Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A, Boussioutas A.

Oncotarget. 2014 Dec 15;5(23):12016-26.

36.

HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling.

Sominsky S, Kuslansky Y, Shapiro B, Jackman A, Haupt Y, Rosin-Arbesfeld R, Sherman L.

Virology. 2014 Nov;468-470:510-523. doi: 10.1016/j.virol.2014.09.007. Epub 2014 Sep 28.

37.

Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.

Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB.

Ann Oncol. 2014 Dec;25(12):2392-7. doi: 10.1093/annonc/mdu454. Epub 2014 Sep 17.

PMID:
25231954
38.

The p53-Mdm2 loop: a critical juncture of stress response.

Levav-Cohen Y, Goldberg Z, Tan KH, Alsheich-Bartok O, Zuckerman V, Haupt S, Haupt Y.

Subcell Biochem. 2014;85:161-86. doi: 10.1007/978-94-017-9211-0_9. Review.

PMID:
25201194
39.

PML tumour suppression and beyond: therapeutic implications.

Gamell C, Jan Paul P, Haupt Y, Haupt S.

FEBS Lett. 2014 Aug 19;588(16):2653-62. doi: 10.1016/j.febslet.2014.02.007. Epub 2014 Feb 15. Review.

40.

Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.

Azad A, Bukczynska P, Jackson S, Haupt Y, Cullinane C, McArthur GA, Solomon B.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):385-94. doi: 10.1016/j.ijrobp.2013.10.043. Erratum in: Int J Radiat Oncol Biol Phys. 2014 May;89(1):226. Haput, Ygal [corrected to Haupt, Ygal].

PMID:
24411611
41.

Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain.

Haupt S, Gamell C, Wolyniec K, Haupt Y.

Cell Death Differ. 2013 Jul;20(7):852-4. doi: 10.1038/cdd.2013.51. No abstract available.

42.

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Wolyniec K, Carney DA, Haupt S, Haupt Y.

Front Oncol. 2013 May 17;3:124. doi: 10.3389/fonc.2013.00124. eCollection 2013.

43.

Increasing intracellular bioavailable copper selectively targets prostate cancer cells.

Cater MA, Pearson HB, Wolyniec K, Klaver P, Bilandzic M, Paterson BM, Bush AI, Humbert PO, La Fontaine S, Donnelly PS, Haupt Y.

ACS Chem Biol. 2013 Jul 19;8(7):1621-31. doi: 10.1021/cb400198p. Epub 2013 May 24.

PMID:
23656859
44.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y.

Cell Cycle. 2013 Jun 1;12(11):1722-31. doi: 10.4161/cc.24805. Epub 2013 May 8.

45.

c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase activity.

Chan AL, Grossman T, Zuckerman V, Campigli Di Giammartino D, Moshel O, Scheffner M, Monahan B, Pilling P, Jiang YH, Haupt S, Schueler-Furman O, Haupt Y.

Biochemistry. 2013 May 7;52(18):3119-29. doi: 10.1021/bi301710c. Epub 2013 Apr 26.

PMID:
23581475
46.

Stimulating p53 down-under: a report from the 1st Australian p53 Workshop.

Neilsen PM, Braithwaite AW, Gamell C, Haupt S, Janic A, Strasser A, Wolyniec K, Haupt Y.

Cell Death Differ. 2013 Dec;20(12):1753-6. doi: 10.1038/cdd.2013.2. Epub 2013 Feb 1. No abstract available.

47.

The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress.

Wolyniec K, Levav-Cohen Y, Jiang YH, Haupt S, Haupt Y.

Oncogene. 2013 Jul 25;32(30):3510-9. doi: 10.1038/onc.2012.365. Epub 2012 Sep 17.

PMID:
22986523
48.

Restoring PML tumor suppression to combat cancer.

Wolyniec K, Chan AL, Haupt S, Haupt Y.

Cell Cycle. 2012 Oct 15;11(20):3705-6. doi: 10.4161/cc.22043. Epub 2012 Sep 14. No abstract available.

49.

MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.

50.

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.

Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I, Corneille V, Kumar B, Woods SJ, Opat S, Johnstone RW, Scott CL, Segal D, Pandolfi PP, Fox S, Strasser A, Jiang YH, Lowe SW, Haupt S, Haupt Y.

Blood. 2012 Jul 26;120(4):822-32. doi: 10.1182/blood-2011-10-387647. Epub 2012 Jun 11. Erratum in: Blood. 2014 Aug 14;124(7):1200.

Supplemental Content

Support Center